Welcome to our dedicated page for Rapt Therapeutics news (Ticker: RAPT), a resource for investors and traders seeking the latest updates and insights on Rapt Therapeutics stock.
RAPT Therapeutics, Inc. (RAPT) is a clinical-stage biopharmaceutical leader developing oral therapies for oncology and inflammatory diseases. This news hub provides investors and industry professionals with verified updates on the company's scientific advancements and corporate developments.
Comprehensive Resource: Track all official announcements including clinical trial milestones, regulatory submissions, financial results, and strategic partnerships. Our curated collection ensures efficient access to material developments affecting RAPT's position in immunology-focused drug discovery.
Key Coverage Areas: Stay informed about CCR4-targeting therapies like tivumecirnon (FLX475) and inflammatory disease candidates such as zelnecirnon (RPT193). Receive updates on FDA communications, research collaborations, and pipeline expansion efforts without speculative commentary.
Strategic Monitoring: Bookmark this page for real-time access to primary source materials. Professionals relying on precision medicine updates will find this centralized repository essential for tracking RAPT's progress in addressing unmet medical needs through innovative immunology approaches.
RAPT Therapeutics (RAPT) reported promising data from preclinical studies to be presented at the American Association for Cancer Research annual meeting. Key findings include the ability of CCR4 antagonists to enhance CAR T-cell therapy's efficacy in solid tumors, with a significant increase in survival rates in murine models. Additionally, small-molecule HPK1 inhibitors demonstrated enhanced T-cell responses, while GCN2 inhibitors showed potential to restore immunity in the tumor microenvironment. These developments highlight RAPT's ongoing commitment to advancing immunology-based therapies for cancer treatment.
SOUTH SAN FRANCISCO, Calif., March 3, 2021 - RAPT Therapeutics (Nasdaq: RAPT) announced CEO Brian Wong will speak at two investor conferences this month. The H.C. Wainwright Global Life Sciences Conference features a company presentation available on March 9 at 7:00 am ET. Wong will also participate in the 33rd Annual Roth Conference on March 15 at 2:00 pm ET, discussing novel immuno-oncology targets. RAPT specializes in oral small molecule therapies for oncology and inflammatory diseases, focusing on advanced drug candidates like FLX475 and RPT193.
RAPT Therapeutics announced that its CEO, Brian Wong, M.D., Ph.D., will present at the 10th Annual SVB Leerink Global Healthcare Conference on February 26, 2021, at 12:00 PM ET. The company focuses on immunology-based therapies for oncology and inflammatory diseases.
RAPT is developing small molecule therapies, including FLX475 and RPT193, targeting C-C motif chemokine receptor 4 (CCR4). For more details, visit the company's website.
RAPT Therapeutics, a clinical-stage biopharmaceutical company, announced that its CEO, Brian Wong, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 3:40 PM Eastern Time. The company focuses on developing oral small molecule therapies for oncology and inflammatory diseases. RAPT has advanced drug candidates targeting C-C motif chemokine receptor 4 (CCR4) and is exploring additional targets in early development. For those interested, the presentation will be available live and archived on their website.
RAPT Therapeutics announced that its executives will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference on Nov. 23, 2020, at 10:00 a.m. ET. The chat will feature Brian Wong, M.D., Ph.D., President and CEO, and Rodney Young, CFO. A replay of the discussion will be available on RAPT’s website. The company focuses on developing oral small molecule therapies for oncology and inflammatory diseases, with notable drug candidates including FLX475 and RPT193, targeting critical immune mechanisms.
RAPT Therapeutics reported a net loss of $14.6 million for Q3 2020, an increase from $10 million in Q3 2019. Research and development expenses rose to $12.9 million due to higher costs for clinical trials of FLX475 and RPT193. In the first nine months of 2020, the net loss totaled $40.2 million, up from $29.8 million in 2019. The company is advancing clinical trials and expects initial data from FLX475 and RPT193 by mid-2021. Cash and cash equivalents stood at $122.8 million as of September 30, 2020.
RAPT Therapeutics (RAPT) announced promising initial results from its Phase 1/2 trial of FLX475, highlighting monotherapy activity and efficacy in combination with pembrolizumab. The trial includes multiple cancer types, with favorable safety data and biomarker support for FLX475’s mechanism. RAPT plans to advance three cancer indications—EBV+ lymphoma, nasopharyngeal cancer, and head and neck cancer—into Phase 2 expansions based on early efficacy data. The company continues patient enrollment and anticipates further updates in the upcoming year.
RAPT Therapeutics announced plans to present initial data from its Phase 1/2 clinical trial of FLX475 for multiple cancer indications on November 16, 2020. The conference call will occur at 8:30 a.m. ET, and a live webcast will be available on the company's website. RAPT focuses on developing oral small molecule therapies for unmet needs in oncology and inflammatory diseases. Their drug candidates target key immune drivers, including CCR4. This data release is expected to provide insights into the efficacy and potential market impact of FLX475.
RAPT Therapeutics, a clinical-stage biopharmaceutical company, announced that President and CEO Brian Wong will present at the Stifel 2020 Virtual Healthcare Conference on November 18, 2020, at 4:00 p.m. ET. The event will be accessible via a live webcast on the RAPT Therapeutics website. The company focuses on developing oral small molecule therapies for unmet needs in oncology and inflammatory diseases. RAPT has advanced drug candidates FLX475 and RPT193, targeting CCR4, along with other developmental targets including HPK1 and GCN2.
RAPT Therapeutics (RAPT) announced the addition of renowned oncology experts Lisa Butterfield, Ph.D. and Lawrence Fong, M.D. to its Scientific Advisory Board. Dr. Butterfield is noted for her work in cancer immunotherapy, while Dr. Fong specializes in various cancers and immunotherapy development. Both will contribute critical insights to advance RAPT's clinical programs, specifically FLX475. Their expertise could enhance the company's efforts in oral small molecule therapies targeting significant unmet needs in oncology and inflammatory diseases.
FAQ
What is the current stock price of Rapt Therapeutics (RAPT)?
What is the market cap of Rapt Therapeutics (RAPT)?
